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Highlights 
 Anecdotal evidence suggests a symptomatic effect of ephedrine in 
myasthenia gravis. 
 This series of randomized controlled n-of-1 trials compared ephedrine to 
placebo. 
 Ephedrine significantly reduced QMG score by 1.0 point. 
 Adverse events were mild, including palpitations, tremor and restlessness. 
 Ephedrine add-on treatment resulted in a small but consistent reduction of 
symptoms 
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ABSTRACT 
 
We studied the effect and safety of ephedrine as add-on treatment for patients with 
myasthenia gravis with acetylcholine receptor antibodies (AChR MG), who do not 
sufficiently respond to standard treatment. Four patients with AChR MG were 
included in a placebo-controlled, double-blind, randomised, multiple crossover series 
of n-of-1 trials. Each n-of-1 trial consisted of 3 cycles, in which two 5-day intervention 
periods were followed by 2 days washout. In each cycle, ephedrine 50mg daily in 2 
doses was compared with placebo in the alternate treatment period. Primary 
outcome was a change in QMG score. Add-on treatment with ephedrine compared 
with placebo improved QMG score by 1.0 point (95% confidence interval 0.21-1.79), 
which was significant for the group of trial patients as well as for the population 
treatment effect. Ephedrine also showed a significant trial average treatment effect 
for all secondary outcomes, improving MG-Composite by 2.7, MG-ADL by 1.0 and 
VAS score for muscle strength by 1.1. Adverse events were mild and included 
palpitations, tremor and restlessness. Although all ECGs were normal, ephedrine 
prolonged the corrected QT interval. Ephedrine as add-on treatment for myasthenia 
gravis resulted in a small but consistent reduction of symptoms and weakness, in 
patients with moderate disease severity. 
  
Page 5 of 23
Lipka AF et al. p6 
 
1. INTRODUCTION 
 
Myasthenia gravis (MG) is a rare autoimmune disease, characterised by fluctuating 
muscle weakness. Many patients initially respond favourably to symptomatic 
treatment with acetylcholinesterase inhibitors (AChIs) that act directly on the 
neuromuscular junction. The next step in treatment often consists of high doses of 
immunomodulating or immunosuppressive drugs, which may have serious side 
effects.[1]  
Anecdotal evidence suggests that some MG patients may benefit from ephedrine as 
add-on treatment to pyridostigmine.[2, 3] Ephedrine might be an alternative which, 
together with AChIs or low-dose prednisone, may reduce disease severity, while 
avoiding the often severe side-effects related to the use of aggressive 
immunomodulating or immunosuppressive therapies. Ephedrine is a 
sympathomimetic agent which mainly affects the adrenergic receptors.[4, 5] Its 
mechanism of action in MG has been investigated, but is not well understood.[6-11] 
An increase in quantal content of the endplate potential and the probability of quantal 
release, as well as an antagonistic effect on acetylcholine receptor (AChR) 
conductance have been described, although these effects occurred at a much higher 
dose than is reached in patients.[7, 9, 12] Moreover, ephedrine could have a direct 
effect on fatigue, which is found in more than 40% of the MG patients and correlates 
poorly with muscle weakness.[13]  
In contrast to congenital myasthenic syndromes, in which a maximal treatment effect 
of ephedrine is observed after weeks to months, the limited number of patients with 
autoimmune MG treated with ephedrine report an onset within hours to days.[2, 10, 
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14] Autoimmune MG is a rare disease with a low prevalence and moreover even 
consists of heterogeneous subgroups, due to differences related to age of onset, sex 
or associated thymic abnormalities. Therefore, a standard randomised controlled trial 
(RCT) is difficult to perform, as also highlighted by the limited success of therapeutic 
development in MG.[15] The likely short-acting nature and rapid onset of response to 
symptomatic treatment in MG in general, permit a crossover design to test the effect  
of ephedrine. A series of n-of-1 trials has the advantage of using each patient as 
their own control in repeated crossover cycles, limiting the required sample size.[16, 
17] We studied the effect and safety of ephedrine as add-on treatment in a series of 
n-of-1 trials in patients with AChR MG who do not sufficiently respond to standard 
treatment.  
 
2. METHODS 
For full details, we refer to the trial protocol, which has been previously 
published.[18]  
2.1 Patient population 
Eligible subjects were adult patients with a diagnosis of generalised MG, based on 
clinical signs or symptoms and confirmed by presence of AChR antibodies. All 
screened subjects were being treated at the Leiden University Medical Center and 
enrolled between October and December 2014. Inclusion criteria were: treatment 
with pyridostigmine and/or low dose prednisone (max. 15mg daily) and/or other 
steroid-sparing immunosuppressive drugs, all of which at a stable dose for at least 6 
weeks. All patients had remaining symptoms of MG that were too mild to justify 
starting or increasing immunosuppressive drugs, but that were not adequately 
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controlled by their current symptomatic treatment. Exclusion criteria were: regular or 
recent (<3 months) intravenous immunoglobulin or plasma exchange, recent (<3 
months) myasthenic crisis, recent (<6 months) or planned thymectomy, any contra-
indication for ephedrine (myocardial ischemia, any cardiac arrhythmia, prolonged QT 
interval, angle-closure glaucoma, current hypertension, poorly regulated diabetes 
mellitus, prostatic hypertrophy or thyrotoxicosis), relevant drug interactions, or 
inability to give informed consent or fill out the study questionnaires. 
2.2 Intervention 
During the n-of-1 trials, add-on treatment with ephedrine 50mg daily in 2 doses was 
compared with placebo, which was similar in shape, colour and flavour to the 
ephedrine tablets. During the entire trial, pyridostigmine, low dose prednisone and 
steroid-sparing drugs such as azathioprine were continued as before, at the same 
dose and time schedule. 
2.3 Design 
Each patient was treated for three single weeks with ephedrine and three single 
weeks with placebo add-on treatment in a randomised, double-blind n-of-1 trial. 
Treatment was administered in three treatment cycles, each consisting of 2 periods 
during which either ephedrine 50mg daily in 2 doses or placebo was administered for 
5 days, followed by a 2-day washout period. This was followed by 5 days of the 
alternate treatment, again with a 2-day washout period. Treatment order within each 
cycle was block-randomised for each patient individually (example shown in Figure 
1). Randomisation was performed by the hospital pharmacy. Patients and 
investigators were blinded to the treatment sequence until completion of each n-of-1 
trial, after which the individual results were discussed and patients were invited to 
participate in a 6-month open label extension phase.  
Page 8 of 23
Lipka AF et al. p9 
 
2.4 Endpoints 
The primary endpoint was the effect of add-on therapy with ephedrine compared with 
placebo on the Quantitative Myasthenia Gravis (QMG) score.[19, 20] The QMG 
score is a severity score for muscle strength and fatigability consisting of 13 items, 
each scored from 0 (normal) to 3 (severe weakness). This endpoint was assessed 
for all patients enrolled, to determine the trial average treatment effect. Only in case 
of significant improvement, the population treatment effect was also assessed to 
determine generalisability to other MG patients. Secondary outcome parameters 
were the MG-Composite, MG-ADL scores and a VAS score for subjective 
assessment of muscle strength in a muscle group predefined by the patient.[21, 22] 
Individual treatment effects were also assessed for all outcome measures. All tests 
were performed on day 5 of treatment periods, at a predefined time and interval after 
all medication. 
Adverse events were monitored during each treatment period using questionnaires, 
which included a list of known side effects of ephedrine, as well as vital signs, 
screening blood tests and ECGs at the end of treatment periods. On the first day of 
both periods in the first treatment cycle, patients were admitted to the hospital  to 
monitor vital signs and adverse events, as well as ECGs at the time of estimated 
maximum serum concentration (Tmax). 
Treatment preference was recorded for each treatment cycle. Blinding was assessed 
by recording presumed randomisation sequence by patient and investigator after 
each treatment period. 
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2.5 Statistics 
Based on our observations during clinical care, we estimated that the standard 
deviation of repeated measurements of QMG within a single person is 2.95. For our 
sample size calculation, we assumed a mean treatment effect of 3.5 with a standard 
deviation of 1. Power calculation by means of Monte Carlo simulation showed a 
sample size of 4 patients would yield 77.2% power to detect a significant difference 
in the trial population. 
For both primary and secondary outcomes measures, a linear model was fitted with 
fixed effects for treatment and patient to test the treatment effect in the trial 
population. This model also produced results for treatment effects in individual 
patients. Only in case of a significant result for an outcome parameter, a linear mixed 
model for these outcomes was fitted with fixed effects for treatment and patient and 
a random treatment effect to determine the population treatment effect, which 
assesses the treatment effect across the population of eligible MG patients.  
Data analysis was performed using R Foundation for Statistical Computing (version 
3.0.2 Vienna, Austria). P-values lower than 0.05 were considered significant. 
2.6 Registration and informed consent 
The study was registered under EudraCT number 2014-001355-23. The study 
protocol was approved by the Medical Ethics Committee of the Leiden University 
Medical Center, and all patients provided written informed consent.  
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3. RESULTS 
3.1 Study population 
We screened 14 patients with AChR MG for entry into the study, of which 5 did not 
meet the eligibility criteria and 4 declined to participate (Figure 1). We included 5 
patients; one patient discontinued before the actual start of the n-of-1 trial and was 
replaced. All four remaining patients completed their n-of-1 trials, baseline 
characteristics of these patients are presented in Table 1. One patient did not 
complete one treatment cycle (due to an acute medical problem in a family member), 
this cycle was excluded and replaced by an extra randomised cycle.  
3.2 Treatment effect 
Add-on treatment with ephedrine compared with placebo resulted in a mean 
improvement in QMG score of 1.0 (95% confidence interval (CI) 0.21-1.79, Table 2), 
which was significant for both the trial average treatment effect (p=0.016) and the 
population treatment effect (p=0.024). Ephedrine treatment also showed a significant 
trial average treatment effect on all secondary outcome parameters; improving MG-
Composite score by 2.7 (p=0.012; 95% CI 0.68-4.65), MG-ADL by 1.0 (p=0.019; 
95% CI 0.19-1.81) and VAS score for individual muscle strength by 1.1 (p=0.033; 
95% CI 0.10-2.07). Population average treatment effects for secondary outcomes did 
not differ significantly from placebo. 
Individual treatment effects showed an individual response on QMG and MG-
Composite scores for one of four patients and a significant improvement of MG-ADL 
and VAS score in another (Figure 2; see also online supplemental figure S1 for 
mean individual scores). Aside from the missed and replaced cycle, compliance was 
100%. One VAS score was missing, constituting the only missing data point.  
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Treatment preference within each cycle showed that patients favoured ephedrine in 
6/12 cycles, placebo in 1 cycle and had no preference in 5 cycles. Based on their 
individual results, three of four patients opted to continue ephedrine treatment in the 
open label extension phase. The fourth patient declined participation because of 
multiple, individually mild side effects which outweighed the small perceived 
treatment effect. Although no patient was officially unblinded during the crossover 
phase, patients correctly guessed the treatment in 68% of treatment periods and 
investigators in 72%.  
3.3 Safety 
Adverse events were limited to mild, transient symptoms (Table 3). Most adverse 
events were only present on a minority of treatment days. Recurring adverse events 
were all previously described side effects and consisted of palpitations, tremor and 
restlessness. None of the adverse events required escape medication or extra 
hospital consultation. Treatment at the current dose did not show a relevant change 
in blood pressure or heart rate, in these patients who were all at low risk for 
cardiovascular disease (see online supplement figure S2A-B). All ECGs recorded 
during the study were normal. Although all conduction intervals, both before and 
after treatment, stayed within the normal range, ephedrine significantly prolonged 
corrected QT (QTc) intervals at estimated maximum serum concentration on day 1 of 
treatment, but not at the end of treatment periods  (see online supplemental Figures 
S2C-D). 
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4. DISCUSSION 
Ephedrine as add-on treatment for myasthenia gravis resulted in a small but 
consistent reduction of symptoms and weakness. The improvement was consistently 
found for all primary and secondary outcome parameters, indicating a clinically 
relevant effect. The current study also showed that a series of n-of-1 trials can be a 
very effective study design to detect even a small effect in a small patient population, 
by replacing the large variance between patients in standard RCTs with smaller 
variance within individual patients. 
Previous clinical trials in myasthenia gravis have reported a decrease of about 2-3.5 
points on the QMG score to be clinically significant.[23-26] Our study shows an effect 
well below this previously defined cut-off point. However, no previous studies have 
tested the effect of adding a second symptomatic treatment, for which the effect can 
realistically be expected to be lower than for immunosuppressive drugs. In our 
opinion, this small effect at a limited risk can be very useful in a subset of MG 
patients with moderate disease severity, when current treatment does not sufficiently 
improve symptoms, but in whom the disease is too mild to justify a more aggressive 
immunosuppressive therapy at the risk of severe side effects. Treatment with 
ephedrine is not without risk either and is associated with cardiovascular events, as 
well as psychiatric, autonomic and gastrointestinal symptoms, although more severe 
events have mostly been described at higher doses or in combination with other 
stimulating drugs.[27, 28] In patients with contra-indications to ephedrine treatment 
risks are unlikely to outweigh the small benefit, but we expect that ephedrine 
treatment is suitable for a small subset of AChR MG patients with intermediate 
disease severity to control remaining symptoms, or prevent or postpone (higher 
dose) immunosuppression.  
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The most important limitation of the study is its small sample size. It can be difficult 
to extrapolate findings in four patients to all MG patients. For this reason, we 
extended our statistical analysis to include a population average treatment effect as 
well as a trial average treatment effect. The consistent improvement in QMG score 
for both models, as well as for the trial average treatment effect on secondary 
outcomes, suggests that our findings are robust. Crossover designs can be 
confounded by unblinding, or by a carry-over effect because of exposure to multiple 
treatment periods. Although we did not formally test for a carry-over effect, QMG and 
MG-Composite scores were actually slightly worse in placebo periods preceded by 
ephedrine, as compared with placebo preceded by placebo, making a relevant carry-
over effect unlikely. Subjective unblinding by either treatment effect or side effects 
did occur in the majority of treatment cycles, as recorded by prediction of treatment 
periods after completed treatment periods during the trial. Correct predictions were 
however mainly present in the two patients with the smallest treatment effect, also 
limiting the potential for confounding.  
Future studies should focus on the possible mechanism of action of ephedrine, for 
example by studying its role in innervation of the neuromuscular junction by 
sympathetic neurons, or correlating results with electrophysiological investigation or 
scales for fatigue.[29] Ephedrine might also improve neuromuscular transmission by 
counteracting the destabilising effect of pyridostigmine on the neuromuscular 
junction.[30, 31] The long term effects and safety of ephedrine treatment in 
autoimmune MG are mostly unknown, therefore a further improvement of the 
treatment effect over months is still possible, as is the case in congenital myasthenic 
syndromes.[10] We aim to elucidate part of this by inclusion of the patients in a 6 
month open label extension phase. The effect of salbutamol, which has a 
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comparable method of action and is also described to have a positive effect in 
congenital myasthenic syndromes, could be a relevant alternative to ephedrine, 
which should be explored in future studies.[30] The current study also highlights the 
potential of a series of n-of-1 trials in rare diseases to detect a short-acting treatment 
effect at limited cost and sample size. 
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FIGURE LEGENDS 
 
Figure 1 Flow Diagram of recruitment, follow-up, and analysis. 
 
Figure 2 Mean treatment effect per cycle for each patient.  
Each patient has completed 3 treatment cycles, for which the benefit of ephedrine 
treatment compared with placebo is shown as dots. Error bars represent 95% 
confidence interval, which are equal for all patients due to the assumption of equal 
variances in the statistical model. 
 
Figure A.1 Individual mean scores during ephedrine and placebo treatment.  
(A) Individual mean QMG scores; (B) MG-Composite scores, (C) MG-ADL scores, (D) VAS 
scores of muscle group chosen by the patient. 
Figure A.2 Cardiovascular effects of ephedrine compared to placebo. 
(A) Systolic (solid lines) and diastolic (dashed lines) blood pressure during ephedrine 
(red lines) and placebo (blue lines) treatment.  
Mean blood pressure at outpatient visit (day 5 of treatment period) is also shown.  
(B) Heart rate at baseline, 30, 60 and 120 minutes after start of ephedrine or placebo 
treatment. These were measured at day 1 of week 1 and 2 for all patients.  
Mean heart rate at outpatient visit (day 5) is also shown.  
(C) Corrected QT interval 60 minutes (estimated time of maximum plasma concentration) 
after start of ephedrine or placebo treatment, measured at day 1 of week 1 and 2.  
* Represents p<0.05 for comparison. 
(D) Corrected QT interval at outpatient visit (day 5 of treatment period).  
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Table 1 Baseline characteristics of study patients. 
 Patient 1 Patient 2 Patient 3 Patient 4 
Age 33 46 53 35 
Gender F F F F 
Disease 
duration 
6 yrs 21 yrs 7 yrs 5 yrs 
AChR titer 
(nmol/L) 
>5.0 >5.0 >5.0 >5.0 
QMG score 7 8 9 16 
MGFA 3A 3B 2A 2A 
MG-
Composite 
10 13 9 5 
Muscle 
group for 
VAS score 
neck bulbar right arm arms 
Medication pyridostigmine 
120mg/d in 2 
doses 
prednisone 
10mg/d;   
AZT 150mg/d 
in 3 doses 
pyridostigmine 
300mg/d in 5 
doses 
pyridostigmine 
300mg/d in 5 
doses 
Thymectomy no yes 
(hyperplasia) 
no yes 
(hyperplasia) 
AChR, acetylcholine receptor; AZT, azathioprine; MGFA, Myasthenia Gravis 
Foundation of America clinical classification scale; QMG, Quantitative Myasthenia 
Gravis score. 
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Table 2 Treatment effect of ephedrine as add-on treatment 
 Baseline 
scores 
Placebo Ephedrine Treatment 
effect  
(± 95% CI) 
P 
valuea 
Population 
significance
b 
      Primary outcome 
QMG  
(0-39) 
10.0 ±4.1 9.5 ± 4.8 8.5 ± 4.5 1.0 (0.21-1.79) p=0.016 p=0.024 
      Secondary outcomes 
MG-C  
(0-50) 
9.3 ±3.3 9.1 ±3.6 6.4 ± 5.3 2.7 (0.68-4.65) p=0.012 p=0.149 
MG-ADL 
(0-24) 
3.5 ±0.6 2.8 ± 1.2 1.8 ± 0.8 1.0 (0.19-1.81) p=0.019 p=0.238 
VAS  
(0-10) 
3.8 ±3.1 4.3 ± 2.4 3.2 ± 2.3 1.1 (0.10-2.07) p=0.033 p=0.198 
Mean primary and secondary outcomes expressed as mean ± standard deviation, 
treatment effect of ephedrine compared to placebo as mean ± 95% confidence 
interval for trial average treatment effect. 
a Trial average treatment effect: fixed model assuming normality, no carry-over 
effects and equal variances for all patients. 
b Population average treatment effect: mixed model, which additionally assumes a 
random treatment effect. 
 
QMG, Quantitative Myasthenia Gravis score; MG-C, Myasthenia Gravis Composite 
scale; MG-ADL, Myasthenia Gravis Activities of Daily Living profile; VAS, visual 
analogue scale 
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Table 3 Adverse events reported in the study. 
Adverse events Ephedrine Placebo 
Nervous system 
  Tremor hands 2 0 
  Nervous / restlessness 2 1 
  Dizziness 1 1 
  Insomnia 2 1 
  Muscle cramps 1 0 
  Headache 1 0 
  Micturition difficulties 1 0 
Lab abnormalities 
  Leukopenia / leukocytosis 2 (3.4; 11.1) 1 (3.7) 
  Anemia 1 (7.4) 0 
  Bilirubinemia 1 (20) 1 (20) 
Cardiovascular 
  Palpitations / tachycardia 3 1 
  Bradycardia 0 1 
Gastro-intestinal / other 
     Abdominal pain 1 0 
     Nausea 1 0 
     Flu-like symptoms 2 1 
Serious adverse events 0 0 
 
All reported adverse events in the study were mild and only intermittently present. 
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